0
0
3/23/23 at 4:35pm
Organization
Yahoo Entertainment
Author
Vandana Singh
35 words
0
Comments
The FDA approved Cidara Therapeutics Inc's (NASDAQ: CDTX) antifungal Rezzayo (rezafungin) under priority review for treating candidemia and invasive...
You are the first to view
https://finance.yahoo.com/news/cidaras-lower-expected-q4-earnings-163533964.html
Create an account
or login to join the discussion